Back to results
US 11,110,161 B2Granted
Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
OwnerCamille Locht, Bernard Mahon +1inventors
InventorsCamille Locht, Bernard Mahon, Heather Kavanagh
Life of this patent
Estimating the term…
Abstract
The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
Claims6
A method of reducing allergen-driven lung eosinophilia in a subject with asthma, the method comprising the step of infecting the subject's respiratory tract with a live attenuated Bordetella pertussis strain which is deficient in tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT).
Dependencies are inferred from the claim text.